Journal
FEBS LETTERS
Volume 586, Issue 13, Pages 1813-1820Publisher
WILEY
DOI: 10.1016/j.febslet.2012.05.020
Keywords
Oncofetal FN; O-GalNAc; EMT; Non-small cell lung cancer; TGF beta 1
Funding
- NIH [R01CA080054]
- Biomembrane Institute
Ask authors/readers for more resources
Epithelial-mesenchymal transition (EMT) has been shown to play a key role in embryogenesis and cancer progression. We previously found that fibronectin (FN) carrying O-GalNAc at a specific site is selectively expressed in cancer and fetal cells/tissues, and termed oncofetal FN (onfFN). Here, we show that (i) a newly-established monoclonal antibody against FN lacking the O-GalNAc, termed normalFN (norFN), is useful for isolation of onfFN, (ii) onfFN, but not norFN, can induce EMT in human lung carcinoma cells, (iii) onfFN has a synergistic effect with transforming growth factor (TGF)beta 1 in EMT induction. (C) 2012 Federation of European Biochemical Societies. Published by Elsevier B. V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available